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Molecular speciesConsiderable progress has recently been made in understanding the role of cardiolipin in mitochondria. In
this brief review, we discuss new data that show how cardiolipin speciﬁcally contributes to the lateral
organization of mitochondrial membranes. We argue that the function of cardiolipin has to be understood in
the context of dynamic membrane assembly rather than static membrane structure, and we propose that
remodeling of cardiolipin, i.e. the formation of uniformly substituted molecular species, may reduce the
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unresolved question for many years. An answer seemed at reach
when Miriam Greenberg's laboratory succeeded to introduce a
yeast strain lacking the enzyme cardiolipin synthase [1]. Initial
work with that mutant has shown reduced activities in pathways,
such as oxidative phosphorylation and mitochondrial protein
import, but surprisingly, the fundamental functions of mitochon-
dria remained intact even in the absence of cardiolipin [2].
Gradually, it has become clear that there is no essential require-
ment for cardiolipin; rather cardiolipin is an ingredient that makes
mitochondria work better. It is fair to say however, that our
insight into the role of cardiolipin has immensely beneﬁted from
studies of cardiolipin-deﬁcient yeast as well as, more recently,
from studies on Barth syndrome, a human disease in which theology, NYU Langone Medical
.: +1 212 263 0648.
Schlame).
ll rights reserved.cardiolipin concentration is reduced and the cardiolipin composi-
tion is altered.
1. Protein interaction of cardiolipin: chaperone-like activity
Perhaps the most prominent physical property of cardiolipin is its
ability to interact by non-covalent bonds with a number of unrelated
proteins, which invokes analogy between cardiolipin and molecular
chaperones. The list of proteins that bind cardiolipin with high
afﬁnity is long and includes, among others, the respiratory
complexes I, III, IV, and V, the carrier family (ADP–ATP-carrier,
phosphate carrier, uncoupling protein), and two peripheral mem-
brane proteins (cytochrome c and creatine kinase) (for a review see
Ref. [3]). Taken together they account for a large portion of the
proteins of the inner mitochondrial membrane; thus most, if not all
proteins of this membrane, are associated with at least some
cardiolipin molecules.
To understand the nature of cardiolipin–protein interactions,
several crystal structures have been analyzed. Indeed, two cardiolipin
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complex III [4,5], complex IV [6], and the ADP–ATP carrier [7]. As
expected, hydrogen bonds to the phosphate groups of cardiolipin and
van-der-Waals bonds to the acyl chains of cardiolipin contributed to
the forces that attract cardiolipin to the protein. The crystal structures
also supported the notion that cardiolipin is well suited to act as a
bridge between two interfacing proteins and may thus promote the
formation of homodimers and other protein complexes.
Crystallographic data are typically interpreted in terms of speciﬁc
and static interactions. However, cardiolipin is not the only
phospholipid in protein crystals, and any notion of speciﬁcity is
inconsistent with the promiscuity of cardiolipin–protein interactions.
Indeed, cardiolipin must possess a great deal of ﬂexibility to adapt to
such different structures as complex III and the ADP–ATP carrier. At
the same time, cardiolipin must exert strong binding forces because
there is a surprising degree of immobilization of cardiolipin
molecules at the protein surface, as revealed by 31P-NMR studies of
the ADP–ATP carrier [8] and of complex V [9]. Broadening of the 31P
resonance is speciﬁc for cardiolipin, i.e. it has not been observed for
any other phospholipid. Cardiolipin competes effectively with
sodium dodecylsulfate for binding sites at the ADP–ATP-carrier and
only complete protein denaturation with heat and chaotropic agents
can release cardiolipin from the carrier [8]. These experiments
suggest that cardiolipin is an integral component of the protein, the
presence of which is critical to folding. Chaperone-like activity of
cardiolipin was also suggested by its ability to stabilize folding
intermediates of the enzyme rhodanese [10]. Although the physio-
logic relevance of this observation remains unclear, it illustrates the
remarkable versatility of cardiolipin to interact with various proteins.
Unfolded rhodanese appeared to have more binding sites for
cardiolipin than for phosphatidylserine [10], which may be the
reason why cardiolipin is a more effective chaperone than other
phospholipids.
2. Lateral segregation of cardiolipin: formation of
membrane domains
Cluster formation is another important physical property of
cardiolipin. Evidence of lateral segregation was ﬁrst obtained in E.
coli, where cardiolipin preferentially localizes to the polar and
septal regions of the cytoplasmic membrane [11]. An elegant
explanation for this phenomenon has been provided on the basis
of the intrinsic curvature of the cardiolipin molecule [12]. According
to this model, microphase separation occurs because the total
energy of the membrane decreases if lipids with high intrinsic
curvature, like cardiolipin, cluster at the bacterial poles. The under-
lying principle is that cardiolipin clusters of a certain size, but not
individual cardiolipin molecules, stabilize the geometry of curved
regions of the membrane. As a result, cardiolipin separates laterally
from other phospholipids. It is not known whether curvature
geometry drives cardiolipin clustering in mitochondria, but the
abundance of high curvature zones in mitochondrial cristae, makes
this idea attractive.
Besides intrinsic curvature, cardiolipin may encourage domain
formation by interacting with proteins. In yeast mitochondria, there is
now ample evidence that cardiolipin promotes the association of
proteins involved in oxidative phosphorylation. Cardiolipinwas found
to be essential for the presence [13], or at least the stability [14] of
respiratory supercomplexes III2IV and III2IV2, and for the association of
respiratory supercomplexes with the ADP–ATP-carrier (AAC) [15]. The
molecularmechanism of this phenomenon is not known and it has not
been determined how many cardiolipin molecules are integrated into
one respiratory supercomplex, i.e. it is unclear whether super-
complexes depend on cardiolipin clusters or just on isolated
cardiolipin molecules. The proteins of oxidative phosphorylation
have an innate tendency to form supramolecular associations, butthe role of cardiolipin is to shift the equilibrium III2+2IV+
AAC2↔ III2IV2AAC2 towards the right side of the equation. Since
these conclusions were drawn entirely from electrophoretic studies,
it is important to note that a kinetic study of complex III/IV activity
in isolated mitochondria also supported a role of cardiolipin in
supercomplex formation [16]. The function of cardiolipin may not be
limited to the aforementioned proteins but may encompass other
complexes, including complex V/tafazzin assemblies [17] or cas-
pase-8 oligomers [18]. Furthermore, proteins like octameric creatine
kinase or cytochrome c, have been shown to induce cardiolipin
clustering in artiﬁcial membranes [19].
3. Acid-base function of cardiolipin: shaping the proton gradient
The titration behavior of cardiolipin suggested the presence of a
stable monovalent anion at neutral pH, implying that the second
proton of cardiolipin dissociates only in a very alkaline milieu [20].
This second proton becomes part of an acid anion formed by hydrogen
bonds between the two phosphates and the central hydroxyl group,
which yields a stable symmetric structure. It has been suggested that
cardiolipin acid anions trap protons at the outer face of the inner
mitochondrial membrane and thus convert the proton gradient into a
transmembrane electrical potential [21]. On the matrix side of the
membrane, cardiolipin may also play a role in proton conduction. This
idea was suggested by the speciﬁc localization of cardiolipin in the
crystal structure of complex III, where cardiolipin was identiﬁed as
part of the proton uptake pathway [4].
The proton buffering capacity of cardiolipin has been implicated in
the formation of mitochondrial cristae. This idea sprung out of a study
on giant unilamellar vesicles prepared from mitochondrial phospho-
lipids [22]. When the vesicles were exposed to a brief pulse-injection
of acid, they temporarily formed cristae-like invaginations, a process
that speciﬁcally required cardiolipin but not any protein. Other acidic
phospholipids were not able to reproduce the effect of cardiolipin in
this experiment. The authors provided a plausible explanation of their
observation by arguing that proton trapping by cardiolipinmay lead to
charge neutralization and consequently to area reduction in the outer
leaﬂet. Since tubular invaginations will reduce the area of the outer
leaﬂet relative to the area of the inner leaﬂet, they may simply
represent the energetically most favorable geometry of the vesicle.
Although the biological relevance of this experiment remains to be
explored, it has demonstrated that sophisticated morphologies can
arise in a minimalist system consisting of a cardiolipin/lipid vesicle
and a local proton gradient.
4. Biosynthesis of cardiolipin: topological aspects
To understand the role of cardiolipin in mitochondria, it is
necessary to know how it is formed and how it is integrated into
mitochondrial membranes. Like all phospholipids, cardiolipin is
synthesized from the universal precursor phosphatidic acid. However,
the biosynthesis of phosphatidic acid occurs in the endoplasmic
reticulum and in the outer mitochondrial membrane, while all
subsequent steps of the de novo formation of cardiolipin are
performed on the matrix side of the inner mitochondrial membrane.
This conclusion was drawn from a study in mitoplasts, where the ﬁrst
and the last enzymes of the de novo pathway, phosphatidate:
cytidylyltransferase and cardiolipin synthase respectively, were
inaccessible to exogenous proteases [23]. The topology of cardiolipin
synthase was corroborated by the ﬁnding that the enzyme can be
inhibited by blockage of the entry of the cofactor Mn2+ into the
mitochondrial matrix [23]. In yeast, cardiolipin synthesis required
Tam41, a protein that also binds to the matrix side of the inner
membrane [24]. Although the function of this protein has not been
identiﬁed, its effect on the intermediates of the cardiolipin pathway,
suggested that Tam41 is involved in early steps of cardiolipin
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cerol [24]. Subsequent to its de novo synthesis, cardiolipin “matures”
by an acyl exchange mechanism that is catalyzed by tafazzin. Since
tafazzin is localized in the mitochondrial periphery, that is the outer
face of the inner membrane [25] and the inner face of the outer
membrane [25,26], cardiolipin has to be translocated across the inner
membrane in order to be remodeled. Again, the translocation
mechanism has remained obscure, although one potential translo-
cator, phospholipid scramblase-3, has been identiﬁed in mitochondria
[27,28].
5. Molecular species of cardiolipin: thermodynamic theory of
membrane assembly
Translocation and acyl remodeling are the last steps of
cardiolipin biosynthesis and these steps must either immediately
precede the incorporation of cardiolipin into the membrane or be an
integral part of the assembly process. We have recently made
surprising observations that have altered our idea of cardiolipin
remodeling and that ultimately favor integration of remodeling and
membrane assembly.
Conventional phospholipid remodeling occurs by repeated cycles
of deacylation and reacylation, catalyzed by calcium-independent
phospholipase A2 (iPLA2) and acyltransferase respectively. However,
genetic inactivation of iPLA2 did not alter cardiolipin remodeling in
Drosophila [29], and genetic ablation of iPLA2γ from mice led only to
an about 30% decrease in remodeled cardiolipin [30], and inhibition
of iPLA2 in insect cells failed to abolish cardiolipin remodeling [31].
These results do not support an essential requirement for iPLA2 in
cardiolipin remodeling. On the other hand, iPLA2 seems to be
involved in the hydrolysis of cardiolipin because deletion of iPLA2
prevented the accumulation of monolyso-cardiolipin in a Drosophila
model of Barth syndrome [29]. If iPLA2 is involved in cardiolipin
hydrolysis but not in cardiolipin remodeling, the question arises
whether the two processes are necessarily linked. Of course, the
current data do not exclude that other phospholipases participate in
cardiolipin remodeling. While the involvement of phospholipases is
still being debated, the enzyme tafazzin is most deﬁnitely involved
in cardiolipin remodeling because tafazzin deﬁciency drastically
alters cardiolipin composition in humans [32,33], ﬂies [34], and
yeast [35]. Interestingly, we found that isolated tafazzin can
exchange fatty acids between two phospholipids in vitro, inferring
that a separate deacylation by iPLA2 may not be necessary for
cardiolipin remodeling [31]. Although tafazzin is a phospholipid–Fig. 1. Proposed mechanism of transacylation by tafazzin. The enzyme (E) exchanges
acyl groups (X, Y, Z) between phospholipid species with the head groups A and B.
Two substrates, a phospholipid and a lysophospholipid, bind to the enzyme simul-
taneously. Acyl exchange between the substrates converts the phospholipid into a
lysophospholipid and the lysophospholipid into a phospholipid. Only the phos-
pholipid dissociates and is replaced by another phospholipid to begin another cata-
lytic cycle. The scheme shows how tafazzin catalyzes the transacylation reaction
XYA+ZYB→ZYA+XYB.lysophospholipid transacylase [36], it requires only trace amounts of
lysophospholipids [31]. Tafazzin reacts with various phospholipid
classes [31,36] and with various acyl species both in sn-1 and sn-2
position [31]. Our current model of the transacylation mechanism of
tafazzin is shown in Fig. 1.
Since tafazzin exchanges acyl groups between phospholipids
without much speciﬁcity for acyl species, head groups, or carbon
positions, the question arises as to how the remarkable acyl speciﬁcity
in cardiolipin is achieved. Throughout the eukaryotic kingdom,
cardiolipin is dominated by molecular species that contain only one
or two types of fatty acids, so structural uniformity and molecular
symmetry prevail [37]. How can tafazzin select speciﬁc acyl groups for
cardiolipin if it does indeed act as a facilitator of unrestricted acyl
exchange between myriads of phospholipid species? A plausible if
hypothetical answer has been given by a mathematical model that
explores the consequences of the transacylation equilibrium [38].
Imagine a large set of molecular species (including different
phospholipids) engages in free acyl exchange. The molecular
composition of the entire ensemblemay change in different directions
and it is straightforward to deﬁne the boundaries within which the
molecular composition can change for any given fatty acid composi-
tion. While tafazzin enables the ensemble of molecular species to
adopt any composition within these boundaries, the ensemble must
ultimately have an internal drive to move into the direction of the
thermodynamic equilibrium. The question then becomes what is the
molecular composition at equilibrium? If all acyl groups make equal
contributions to the total free energy of the ensemble regardless of the
phospholipids they are bound to, fatty acids would distribute
randomly. If, on the other hand, some molecular species have a
lower free energy than others, these species will accumulate in the
transacylation equilibrium [38].
The model makes essentially two predictions. First, it suggests that
acyl speciﬁcity may arise from the transacylation reaction in the
absence of enzymatic speciﬁcity, merely due to speciﬁc interactions
within the membrane. These interactions have not been deﬁned, but
they may include lipid–protein associations or lipid clusters as
discussed in Sections 1 and 2, or they may include other character-
istics of mitochondrial membranes. It is intuitive that symmetric
cardiolipin species are better suited to crosslink proteins and that
uniformly substituted cardiolipin species have a greater tendency to
cluster than heterogeneous cardiolipin molecules. Second, the model
suggests that tafazzin confers compositional ﬂexibility to phospholi-
pids. Since tafazzin can “move” the molecular composition to any
point within a mathematically deﬁned spectrum of compositions, it
can easily adapt the molecular composition to a changing micro-
environment. A changing microenvironment is most likely encoun-
tered during the step-by-step assembly of mitochondrial membranes,
in particular during the assembly of supramolecular structures such as
respiratory supercomplexes. Thus we speculate that tafazzin lowers
the energy barrier of the assembly process by constantly adapting the
molecular composition of phospholipids.
In conclusion, tafazzin is a transacylase that redistributes acyl
groups between phospholipids, which may generate speciﬁc patterns
of molecular species in cardiolipin. The speciﬁc patterns are
dependent on the type of mitochondria rather than the type of
tafazzin. For instance, when human tafazzin was expressed in yeast
[39], Drosophila (unpublished data), or Sf9 insect cells [31], the
resulting changes in the cardiolipin pattern did not reﬂect the
composition of human cardiolipin. In all three examples, human
tafazzin was able to reshufﬂe the types of fatty acids that are
characteristic of the host mitochondria. While it is clear from the
above that transacylations are critical for the fatty acid composition of
mitochondrial phospholipids, transacylations may also play a role in
other aspects of phospholipid metabolism. For instance, transacyla-
tions are involved in the distribution of arachidonic acid among the
molecular species of major glycerophospholipids [40].
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